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Supplementary figures 
 
 
Figure S1: Time points of the first and follow up questionnaires for the Rotterdam Study cohorts 
Diagram of the included individuals and contact moments for the Rotterdam Study. Green boxes: RS-I cohort, yellow boxes: RS-II cohort; purple 
boxes: RS-III cohort. A more elaborate figure with information about the follow up after 2013 is published by Ikram et al.1. 
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Figure S2: Distribution curves of the PRS313 in the Rotterdam Study cohort 
Abbreviations: BC, Breast Cancer; PRS, Polygenic Risk Score 
The standardised PRS313 was plotted against the density for different groups in the Rotterdam Study. (A) 
incident BC cases and unaffected women; (B) incident BC cases, unaffected women who developed 
another type of tumour and unaffected women who did not develop another type of tumour. Women who 
developed another type of tumour before inclusion in the Rotterdam Study were excluded (N=114); (C) 
invasive incident BC cases, in situ incident BC cases and unaffected women; (D) Incident BC cases who 
developed one breast tumour, incident BC cases who developed a second primary breast tumour after 
one year and unaffected women. Women who developed a second primary breast tumour within one year 
were excluded (N=17). Unaffected women include all those that did not develop BC. 
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Figure S3: Cumulative breast cancer incidence in the Rotterdam study stratified on PRS313 
quintiles 
Abbreviations: PRS, Polygenic Risk Score. 
Kaplan Meier plot for the cumulative breast cancer incidence since the time of inclusion in the Rotterdam 
Study. The cohort is stratified in quintiles of the PRS313, based on the distribution of unaffected women in 
the cohort.   
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Figure S4: Calibration plots of the predicted 10-year risk based on BOADICEA and the observed risk in the Rotterdam Study cohort  
Abbreviations: BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; PRS, Polygenic Risk Score. 
10-year cumulative BC risks were calculated for all women included in the Rotterdam Study before the age of 70 years, using BOADICEA v5. The 
difference between the observed and predicted risk is shown per decile of the predicted risk, including 95% confidence intervals, for different sets 
of included variables. Using age only (A), age and risk factors (B), age and the PRS (C) and age, risk factors, and the PRS (D).  
6 
 
 
 
Figure S5: Change in 10-year risk by adding risk factors or the PRS313 in the BOADICEA model 
Abbreviations: BC, Breast Cancer; BOADICEA, Breast and Ovarian Analysis of Disease Incidence and 
Carrier Estimation Algorithm; PRS, Polygenic Risk Score. 
10-year cumulative BC risks were calculated for all women included in the Rotterdam Study before the 
age of 70 years, using BOADICEA v5. Women were considered as incident BC cases if they developed 
BC within 10 years of follow up (shown in red). (A) Risk-change by adding the PRS313 in the BOADICEA 
model (y-axis) including age and risk factors (x-axis). (B) Risk-change by adding risk factors in the 
BOADICEA model (y-axis) including age and the PRS313 (x-axis).  
7 
 
 
Figure S6: Percentage of unaffected women and incident breast cancer cases in different 10-year 
risk categories 
Abbreviations: BC, Breast Cancer; BOADICEA, Breast and Ovarian Analysis of Disease Incidence and 
Carrier Estimation Algorithm; PRS, Polygenic Risk Score. 
Bar plot of the percentages of women assigned to the different 10-year cumulative BC risk categories 
(<1.5%; 1.5%-3.5%; 3.5%-5%; 5%-8%; >8%) as calculated with BOADICEA v5 using two sets of 
variables. Including age and the PRS313 (A) and including age, risk factors and the PRS313 (B). These 
risks were calculated for all women included in the Rotterdam Study below the age of 70 years. Women 
were considered affected if they developed BC within 10 years of follow up.  
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Supplementary tables 
 
Table S1: Characteristics of the Rotterdam Study cohort 
    Total cohort Subcohorta 
    Unaffected Incident BC Unaffected Incident BC 
Number   6202 320 4214 163 
Rotterdam Study cohort 
RS-I 3536 227 1821 152 
RS-II 1057 59 796 50 
RS-III 1609 34 1525 33 
Birth cohort 
<1900 54 1 0 0 
1900-1910 487 9 0 0 
1910-1920 996 46 0 0 
1920-1930 1441 106 976 77 
1930-1940 1293 97 1235 97 
1940-1950 1087 42 1087 82 
1950-1960 811 18 811 18 
1960 33 1 33 1 
Age at inclusion 
Mean 66.1 65 59.9 60.4 
Range 45.8-99.2 45.8-96.3 45.8-70.0 45.8-70.0 
Age at diagnosis 
Mean -  72.7  - 65.3 
Range  - 48-100  - 48.0-79.0 
Invasiveness first BC 
Invasive  - 286  - 142  
In situ  - 34  - 21  
Asynchronous second BCb 
 All  - 59  - 44 
Invasive  - 59  - 44 
In situ  - 0  - 0 
Other incident tumourc   728 16 450 13 
Risk factors  
Height in cm 
Mean 162.3 163.0 164.0 164.3 
Unknown 137 (2%) 5 (2%) 9 (0.2%) 3 (2%) 
Alcohol use in grams per day 
Mean  6.3 7.1 6.8 6.8 
Unknown 506 (8%) 11 (3%) 742 (18%) 34 (21%) 
Age menarche 
Mean 13.5 13.3 13.4 13.3 
Unknown 317 (5%) 11 (3%) 102 (2%) 4 (2%) 
Age menopause 
Mean 48.8 49.2 48.6 49.4 
Unknown 473 (8%) 24 (8%) 255 (6%) 15 (9%) 
9 
 
  Premenopausal  - - 187 5  
Number of children 
0 482 25 408 15  
1 811 39 642 22 
2 1819 93 1549 52 
>2 1443 80 1031 41 
Unknown 1647 (27%) 83 (26%) 584 (14%) 33 (20%) 
Age at first childbirth 
Mean 25.2 25.2 25.0 25.6 
Unknownd 47 (1%) 5 (2%) 603 (14%) 34 (21%) 
Use of oral contraception 
Never 2346 137 1238 50 
Ever 2774 126 2665 90 
Unknown 1082 (17%) 57 (18%) 311 (7%) 23 (14%) 
Use of hormone replacement 
therapy 
Never 5050 254 3416 128 
Ever 994 62 758 32 
Unknown 158 (2.5%) 4 (1%) 40 (1%) 3 (2%) 
Body Mass Index 
Mean 27.0 27.7 27.0 27.8 
Unknown 141 (2%) 5 (2%) 38 (1%) 3 (2%) 
Standardised PRS313 
Mean 0 0.45 -0.01 0.57 
SD 1.00 1.05 1.00 1.02 
Abbreviations: BC, Breast Cancer; PRS, Polygenic Risk Score; RS, Rotterdam Study; SD, Standard 
Deviation. 
a Subcohort of women with an age of inclusion in the Rotterdam Study up to age 70 
b Development of a second primary breast tumour at least one year after the first primary breast tumour. 
c For women who developed BC during follow up, other tumours were only reported in this study if the 
other tumour was diagnosed before the BC diagnosis. 
d For women known to have children. 
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Table S2: 313 breast cancer associated variants included in the Polygenic Risk Score 
First 7 columns of the table are published by Mavaddat et al.2 
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Table S3: Number of included women diagnosed with other type of tumours 
ICD10 Tumour descriptiona  
Unaffected 
women 
Incident BC 
casesb Total 
C00 Lip 5   5 
C02 Tongue 2   2 
C03 Gum 1   1 
C04 Floor of mouth 1   1 
C05 Palate 2   2 
C06 Mouth 2   2 
C08 Major salivary glands 1   1 
C09 Tonsil 2   2 
C10 Oropharynx 1   1 
C15 Oesophagus 27   27 
C16 Stomach 21   21 
C17 Small intestine 3 1 4 
C18 Colon 90 1 91 
C19 Rectosigmoid 33 2 35 
C20 Rectum 38 1 39 
C21 Anus and anal canal 5   5 
C22 Liver and intrahepatic bile ducts 8   8 
C23 Gallbladder 2   2 
C24 Biliary tract 6   6 
C25 Pancreas 44   44 
C26 Digestive organs 4   4 
C32 Larynx 1   1 
C34 Bronchus & lung 112   112 
C39 Respiratory system and intrathoracic organs 1   1 
C40 Bone and articular cartilage of limbs 2   2 
C43 Melanoma 27 2 29 
C45 Mesothelioma 4   4 
C48 Retroperitoneum and peritoneum 1   1 
C49 Connective and soft tissue 3   3 
C51 Vulva 6   6 
C52 Vagina 1   1 
C53 Cervix uteri 10 1 11 
C54 Corpus uteri 48 2 50 
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C56 Ovary 24   24 
C57 Female genital organs 1   1 
C64 Kidney, except renal pelvis 16 1 17 
C65 Renal pelvis 4   4 
C66 Ureter 1   1 
C67 Bladder 24 1 25 
C69 Eye and adnexa 5   5 
C70 Meninges 1   1 
C71 Brain 13   13 
C73 Thyroid gland 4 1 5 
C80 Malignant neoplasm unspecified 37 1 38 
C81 Hodgkin lymphoma 1   1 
C82 Follicular lymphoma 6 1 7 
C83 Non-follicular lymphoma 13   13 
C84 Mature T/NK-cell lymphomas 2   2 
C85 Non-Hodgkin lymphoma 11   11 
C88 Immunoproliferative diseases 1   1 
C90 
Multiple myeloma and malignant plasma cell 
neoplasms 
19 1 20 
C91 Lymphoid leukaemia 12   12 
C92 Myeloid leukaemia 17   17 
C93 Monocytic leukaemia 2   2 
Total   728 16 744 
Abbreviations: BC, Breast Cancer; ICD, International Classification of Diseases and Related Health 
Problems 
a ICD10 tumour description3  
b Other tumours are only reported if a women developed this tumour before the BC diagnosis 
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Table S4: Descriptives for the standardised PRS313  
    Number Mean SD SE 95% CI 
Unaffected  
Total 6202 0.00 1.00 0.01 -0.02-0.02 
Without other tumour 5360 -0.01 1.01 0.01 -0.03-0.02 
Incident other tumoura 728 0.03 0.98 0.04 -0.04-0.10 
Incident BC 
cases 
Total 320 0.45 1.05 0.06  0.34-0.57 
Invasive BC 286 0.46 1.05 0.06  0.34-0.58 
In situ BC 34 0.36 1.06 0.18  0.00-0.72 
One primary breast tumour 244 0.46 1.00 0.06  0.33-0.59 
Asynchronous second BCb 59 0.51 1.27 0.17  0.19-0.84 
Abbreviations: BC, Breast Cancer; CI, Confidence Interval; PRS, Polygenic Risk Score; SD, Standard 
Deviation; SE, Standard Error. 
a Women who developed another type of tumour before inclusion in the Rotterdam Study were excluded 
(N=114) 
b Development of a second primary breast tumour at least one year after the first primary breast tumour. 
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